Intellia Therapeutics Inc. (NTLA)
Wall Street Analysts See a 408.63% Upside in Intellia Therapeutics (NTLA): Can the Stock Really Move This High?
The mean of analysts' price targets for Intellia Therapeutics (NTLA) points to a 408.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Intellia Therapeutics, Inc. (NTLA) BofA Securities 2025 Healthcare Conference (Transcript)
Intellia Therapeutics, Inc. (NASDAQ:NTLA ) BofA Securities 2025 Healthcare Conference May 13, 2025 7:20 PM ET Company Participants Ed Dulac - CFO Conference Call Participants Alec Stranahan - BofA Securities Alec Stranahan Hello, everyone. Thanks for joining the session with Intellia Therapeutics on day 1 of the 2025 Bank of America Healthcare Conference.
Intellia Therapeutics Shares Have Struggled, But It's Now Go-Time (Rating Upgrade)
Investors who've been looking for problems at Intellia Therapeutics have, during the past year, had an easy time finding them. A tendency to misinterpret helped. Investors complained about test results that were fine with medical experts and the FDA. The Street hated when NTLA dropped a lesser program and laid off some staff members. On 5/8/25, the Company reported further progress with two treatments that are now ensconced in Phase III of testing—a level only a third of new drugs reach.
Intellia's Q1 Loss Narrower Than Expected, Pipeline in Focus, Stock Up
NTLA reports better-than-expected first-quarter 2025 results. The company provides updates on its pipeline candidates.
Intellia Therapeutics, Inc. (NTLA) Q1 2025 Earnings Call Transcript
Intellia Therapeutics, Inc. (NASDAQ:NTLA ) Q1 2025 Results Conference Call May 8, 2025 8:00 AM ET Company Participants Brittany Chaves - Senior Manager of Investor Relations John Leonard - President and Chief Executive Officer David Lebwohl - Chief Medical Officer Ed Dulac - Executive Vice President and Chief Financial Officer Birgit Schultes - Executive Vice President and Chief Scientific Officer Conference Call Participants Gena Wang - Barclays Kostas Biliouris - BMO Capital Markets Luca Issi - RBC Maury Raycroft - Jefferies Mitchell Kapoor - H. C. Wainwright Jay Olson - Oppenheimer Rick Bienkowski - Cantor Fitzgerald Yanan Zhu - Wells Fargo Troy Langford - TD Cowen Jake Roberge - William Blair Brian Cheng - JPMorgan William Pickering - Bernstein David Lebowitz - Citi Operator Good morning, and welcome to Intellia' First Quarter 2025 Financial Results Conference Call.
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates
Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $1.10 per share versus the Zacks Consensus Estimate of a loss of $1.26. This compares to loss of $1.06 per share a year ago.
Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline
Intellia Therapeutics (NTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Intellia Therapeutics, Inc. (NTLA) Recently Broke Out Above the 50-Day Moving Average
Intellia Therapeutics, Inc. (NTLA) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, NTLA broke out above the 50-day moving average, suggesting a short-term bullish trend.
Wall Street Analysts Think Intellia Therapeutics (NTLA) Could Surge 392.81%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 392.8% in Intellia Therapeutics (NTLA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Intellia Focuses on Pipeline Development Amid Stiff Competition
Studies on NTLA's gene-edited therapy, nex-z, are progressing well while other pipelines are picking up pace. Stiff competition in the target market is a woe.
NTLA Genome-Editing Therapy Gets FDA's RMAT Tag for New Indication
The FDA bestows a Regenerative Medicine Advanced Therapy tag to Intellia's nex-z for treating transthyretin amyloidosis with cardiomyopathy.
Intellia Therapeutics, Inc. (NTLA) Barclays 27th Annual Global Healthcare Conference (Transcript)
Intellia Therapeutics, Inc. (NASDAQ:NTLA ) Barclays 27th Annual Global Healthcare Conference March 11, 2025 3:00 PM ET Company Participants John Leonard - President and CEO Conference Call Participants Gena Wang - Barclays Gena Wang Good afternoon, everyone. My name is Gena Wang.
